Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Lei Xu, Kentaro Imai, Jacqueline Willemann-Rogerio, David I. Quinn, Thomas Powles
Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Poznan University of Medical Sciences, University Hospital of Lord’s Transfiguration, Samsung Medical Center, University of Glasgow, Royal Perth Hospital, Edinburgh Cancer Research, University of Edinburgh, University Hospital Ostrava, Taipei Veterans General Hospital, Asan Medical Center, University of Ulsan, Imperial College Healthcare NHS Trust, Centre Hospitalier Universitaire de Besançon, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Fundación Arturo López Pérez, Abramson Cancer Center, University of Pennsylvania, Provincial Polyclinical Hospital in Toruń, Merck & Co., Inc., Rahway, NJ, USA (United States), USC Norris Comprehensive Cancer Center, Queen Mary University of London, Cancer Research UK, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4212878595